Volume : 12, Issue : 03, March – 2025
Title:
TEPROTUMUMAB AND ITS IMPACT ON QUALITY OF LIFE IN PATIENTS WITH THYROID EYE DISEASE: A REVIEW
Authors :
Abdulmajeed M. Algethami
Abstract :
Thyroid eye disease (TED) significantly affects patients’ quality of life (QoL), leading to substantial physical, emotional, and social impairments. Teprotumumab, a fully human monoclonal antibody targeting the insulin-like growth factor-1 receptor, has emerged as a novel treatment option for moderate to severe TED. This review explores the mechanism and efficacy of Teprotumumab, its impact on patients’ QoL, and the importance of integrating QoL assessments into clinical practice. Current evidence highlights that Teprotumumab not only alleviates ocular symptoms but also enhances overall well-being, emphasizing the need for holistic management strategies in TED.
Keywords: Thyroid Eye Disease, Grave’s Disease, Quality of life, Teprotumumab
Cite This Article:
Please cite this article in press Abdulmajeed M. Algethami et al., Teprotumumab And Its Impact On Quality Of Life In Patients With Thyroid Eye Disease: A Review., Indo Am. J. P. Sci, 2025; 12(03).
Number of Downloads : 10
References:
1. Smith TJ, et al. Teprotumumab treatment for thyroid eye disease: A randomized controlled trial. JAMA. 2017;318(20):2032-2043. doi:10.1001/jama.2017.17368
2. Perros P, et al. The impact of thyroid eye disease on quality of life: a review of the literature. Thyroid. 1998;8(6):543-550. doi:10.1089/thy.1998.8.543
3. Watt T, et al. The impact of Graves’ ophthalmopathy on quality of life. Eur J Endocrinol. 2006;155(5):809-814. doi:10.1530/eje.1.02281
4. Douglas RS, et al. Real-world evidence of Teprotumumab effectiveness in thyroid eye disease. Am J Ophthalmol. 2020;213:131-137. doi:10.1016/j.ajo.2020.07.026
5. Douglas RS, et al. Teprotumumab for the treatment of moderate-to-severe thyroid eye disease: safety and efficacy results of a randomized controlled trial. Lancet Diabetes Endocrinol. 2021;9(6):362-371. doi:10.1016/S2213-8587(21)00042-9
6. Salvi M, Bartalena L. Thyroid eye disease: An update on recent advances in diagnosis and treatment. Clin Endocrinol (Oxf). 2020;92(5):431-439. doi:10.1111/cen.14155
7. Gagnon KE, et al. The role of Teprotumumab in improving emotional and functional outcomes in TED. Thyroid. 2021;31(3):377-384. doi:10.1089/thy.2020.0576
8. Smith TJ, et al. Teprotumumab for thyroid eye disease: How it works and the significance of improvements in quality of life. Endocrinol Metab Clin North Am. 2021;50(3):749-764. doi:10.1016/j.ecl.2021.05.007
9. Lee SS, et al. Quality of life assessment in patients with thyroid eye disease. Clin Exp Ophthalmol. 2018;46(5):435-444. doi:10.1111/ceo.13126
10. Bartalena L, et al. Managing thyroid eye disease: The role of quality of life measures. Curr Opin Endocrinol Diabetes Obes. 2020;27(4):307-314. doi:10.1097/MED.0000000000000568
11. Gagnon KE, et al. Long-term follow-up and durability of treatment outcomes in thyroid eye disease. J Clin Endocrinol Metab. 2021;106(5):1554-1563. doi:10.1210/clinem/dgab121
12. Douglas RS, et al. Impact of Teprotumumab on emotional and functional outcomes in TED. Thyroid. 2017;27(9):1329-1337. doi:10.1089/thy.2017.0389
13. Smith TJ. Teprotumumab for thyroid eye disease: An evaluation of long-term safety and efficacy. Endocrinol Metab Clin North Am. 2019;48(4):1159-1169. doi:10.1016/j.ecl.2019.08.004
14. Bartalena L, et al. Long-term outcomes of Teprotumumab in patients with thyroid eye disease. Thyroid. 2017;27(9):1154-1164. doi:10.1089/thy.2017.0293
15. Krassas GE, et al. Impact of thyroid eye disease on quality of life: A review. Eur J Endocrinol. 2017;176(6):669-676. doi:10.1530/EJE-17-0006
16. Gagnon KE, et al. The impact of Teprotumumab on emotional and functional outcomes in TED. Thyroid. 2021;31(3):377-384. doi:10.1089/thy.2020.0576
17. Tsai JK, et al. Teprotumumab treatment for thyroid eye disease: A review. Endocrinol Rev. 2019;40(2):564-577.
18. Smith TJ, et al. Teprotumumab for thyroid eye disease: How it works and the significance of improvements in quality of life. Endocrinol Metab Clin North Am. 2021;50(3):749-764.
19. Salvi M, et al. Thyroid eye disease: Review of a rapidly evolving field. Clin Endocrinol (Oxf). 2019;90(6):736-745.
20. Bartalena L, et al. Managing thyroid eye disease: The role of quality of life measures. Curr Opin Endocrinol. 2020;27(4):307-314.